American biotechnologists have, for the first time, restored youthful characteristics in aged human liver cells using epigenetic reprogramming. The company is preparing for clinical trials to confirm the effectiveness of this method and to expand its use for treating liver diseases and rejuvenating other tissues.
For the first time, the technology of epigenetic cell rejuvenation, previously tested successfully on animals, is moving into clinical trials in humans. The new drug ER-100 could pave the way for restoring retinal cell function and treating age-related eye diseases.
Researchers at KAIST have developed a method that allows macrophages to be reprogrammed directly within tumors, turning them into active cancer fighters. This approach could enhance the effectiveness of immunotherapy and simplify the treatment of complex types of tumors.